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Compound heterozygous 
mutations in TGFBI cause a severe 
phenotype of granular corneal 
dystrophy type 2
Ikhyun Jun1,2,4, Yong Woo Ji2,4, Seung‑il Choi1, Bo Ram Lee1, Ji Sang Min2 & 
Eung Kweon Kim1,3* 
We investigated the clinical and genetic features of patients with severe phenotype of granular 
corneal dystrophy type 2 (GCD2) associated with compound heterozygosity in the transforming 
growth factor‑β‑induced (TGFBI) gene. Patients with severe GCD2 underwent ophthalmic examination 
(best‑corrected visual acuity test, intraocular pressure measurement, slit‑lamp examination, and 
slit‑lamp photograph analysis) and direct Sanger sequencing of whole‑TGFBI. The patient’s family was 
tested to determine the pedigrees. Five novel mutations (p.(His174Asp), p.(Ile247Asn), p.(Tyr88Cys), 
p.(Arg257Pro), and p.(Tyr468*)) and two known mutations (p.(Asn544Ser) and p.(Arg179*)) in TGFBI 
were identified, along with p.(Arg124His), in the patients. Trans‑phase of TGFBI second mutations was 
confirmed by pedigree analysis. Multiple, extensive discoid granular, and increased linear deposits 
were observed in the probands carrying p.(Arg124His) and other nonsense mutations. Some patients 
who had undergone phototherapeutic keratectomy experienced rapid recurrence (p.(Ile247Asn) and 
p.(Asn544Ser)); however, the cornea was well‑maintained in a patient who underwent deep anterior 
lamellar keratoplasty (p.(Ile247Asn)). Thus, compound heterozygosity of TGFBI is associated with 
the phenotypic variability of TGFBI corneal dystrophies, suggesting that identifying TGFBI second 
mutations may be vital in patients with extraordinarily severe phenotypes. Our findings indicate the 
necessity for a more precise observation of genotype–phenotype correlation and additional care when 
treating TGFBI corneal dystrophies.
Several transforming growth factor beta-induced gene (TGFBI) mutations, with corneal deposit formation and 
specific clinical phenotypes, have been reported to  date1,2. Components of TGFBI product, i.e., transforming 
growth factor beta-induced protein (TGFBIp), have been detected in the  deposits3,4, indicating a relation between 
TGFBI mutation and deposit formation. Granular corneal dystrophy type 2 (GCD2) is an autosomal dominant 
disorder caused by p.(Arg124His) mutation of TGFBI5. While a homozygote may show severe corneal deposits 
from the age of 3  years6, slow and progressive accumulation of granular deposits, linear deposits, and diffuse haze 
in the corneal stroma with aging is a characteristic pathologic feature of heterozygous  GCD27,8. The phenotypic 
variability of heterozygous GCD2 (p.(Arg124His) mutation) in the cornea is considerable, from few subtle white 
dots to multiple severe opacities throughout the stroma, even at relatively young  ages9,10. However, the possible 
cause or mechanism of this variability has not yet been elucidated.
Severe phenotypic features due to double mutations in TGFBI have been  reported11–23. In the current study, 
we detected five novel and two known mutations, occurring as a compound heterozygote in TGFBI along 
with p.(Arg124His), which result in a very severe phenotypic variant of GCD2. In addition, we have presented 
each proband’s family pedigree. Interestingly, individuals carrying a nonsense mutation in an allele and no 
p.(Arg124His) mutation in the opposite allele did not show an abnormal phenotype. We further performed 
in vitro experiments to investigate the effect of the identified mutations as well as p.(Arg124His) on TGFBIp 
aggregation.
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Results
The compound heterozygous mutations p.(Arg124His) and p.(His174Asp) in TGFBI. A 
35-year-old woman (Proband 1; Family 1-Patient II-3) with confluent granular deposits, dense linear deposits, 
and extremely severe diffuse haze on her cornea visited our clinic. Her best-corrected visual acuity (BCVA) 
was 20/40 in both eyes (Fig. 1a). Genetic analysis revealed p.(Arg124His) and p.(His174Asp) missense muta-
tions in TGFBI (Table 1). Her 38-year-old brother showed more diffuse haze in both eyes than in any usual 
GCD2 heterozygote of his age (Fig. 1a). The cornea of the proband’s father, who only harboured a heterozy-
gous p.(His174Asp) mutation, was clear, whereas the mother, who was a GCD2 heterozygote, showed typi-
cal heterozygotic GCD2 phenotype, i.e., annular granular deposits and deep linear deposits in the cornea. The 
pedigree analysis showed both the proband and her brother to have inherited the mutations in trans-phase (i.e., 
p.(His174Asp) from the father and p.(Arg124His) from the mother) (Fig. 1b).
A 49-year-old man (Proband 2; Family 2-Patient II-2), not related to Family 1, visited our clinic with visual 
disturbances complaint; he presented with very severe diffuse haze and stromal opacities compared to other 
patients (Fig. 1c). Genetic and segregation analyses of the patient’s family showed compound heterozygous 
p.(Arg124His) and p.(His174Asp) mutations in TGFBI (Supplementary Fig. S1a).
Figure 1.  TGFBI p.(His174Asp) variant aggravates granular corneal dystrophy 2 caused by p.(Arg124His) 
mutation in a compound heterozygote. (a) Slit-lamp photographs of the members of Family 1. Severe confluent 
granular deposits with lattice deposits were observed in Proband 1. Her brother’s eyes also showed severe 
snowflake-like corneal deposits. (b) Pedigree of Family 1 showed both proband and her brother to have 
inherited the mutations in trans-phase. (c) Slit-lamp photographs of Family 2. The cornea of Proband 2 showed 
intensive opacities, whereas that of his mother showed mild phenotype. (d) Slit-lamp photograph of Proband 3 
showed coarse granular and lattice deposits.
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A 41-year-old woman (Proband 3; Family 3), not related to either Family 1 or 2, presented with severe pheno-
typic variation (Fig. 1d) and showed both p.(His174Asp) and p.(Arg124His) mutations in TGFBI upon genetic 
analysis. We, however, could not trace her pedigree, since the patient refused clinical evaluation and genetic 
analysis of her family members.
To investigate the molecular mechanism of why the phenotype of GCD2 aggravate when p.(His174Asp) 
mutation is accompanied, the degree of aggregation of p.(His174Asp), and p.(Arg124His) mutant proteins was 
examined. Mixture of the cultured media of p.(His174Asp) expressing cells and p.(Arg124His) corneal fibro-
blasts, showed increased TGFBIp oligomer and aggregate formation during in vitro experiments (Supplementary 
Fig. S2, see also Supplementary Note).
Compound heterozygous mutations, p.(Arg124His) and p.(Ile247Asn), in TGFBI. A 35-year-
old man (Proband 4; Family 4-Patient III-1) was referred to our hospital with severe diffuse corneal haze causing 
visual disturbance, which recurred after phototherapeutic keratectomy (PTK) at another clinic. We obtained 
photographs of the cornea, acquired at the other clinic at the age of 25 years; he had undergone PTK of the right 
cornea at the age of 24 years, while the left cornea had not been treated. The photograph of his left untreated 
cornea acquired at the age of 25  years (Fig.  2a left first) showed extremely severe diffuse haze and granular 
deposits. Both p.(Ile247Asn) and p.(Arg124His) missense mutations were detected in TGFBI (Table  1), and 
pedigree analysis confirmed the mutations to be located in different alleles (Fig.  2b). The proband’s father, 
aged 77 years, showed clear corneas (Fig. 2c) with only p.(Ile247Asn) mutation, whereas the proband’s mother 
harboured p.(Arg124His) mutation and her cornea showed typical GCD2 features. Moreover, the 62-year-old 
paternal uncle of the proband harboured only p.(Ile247Asn) mutation with a clear cornea. Since the proband 
experienced decreased visual acuity, additional PTK for each eye was performed separately in our clinic. Corneal 
opacity of the proband, however, recurred rapidly, becoming diffuse and dense even after several PTK ablations. 
After deep anterior lamellar keratoplasty (DALK) of his left eye, the cornea has remained clear since the past 
3 years (Fig. 2a).
Similar to p.(His174Asp), the p.(Ile24yAsn) mutation was also examined for the aggregation of TGFBIp. 
Mixture of the cultured media of p.(Ile247Asn) expressing cells and p.(Arg124His) corneal fibroblasts, showed 
increased TGFBIp oligomer and aggregate formation during in vitro experiments (Supplementary Fig. S2, see 
also Supplementary Note).
Heterozygous patients with GCD2 having additional p.(Tyr88Cys), p.(Arg257Pro), or 
p.(Asn544Ser) mutation in a different TGFBI allele. A 17-year-old woman (Proband 5; Family 
Table 1.  Detected mutations increasing severity of granular corneal dystrophy 2 as a compound heterozygote 
with p.(Arg124His) in this study. Abbreviations: Dam, damaging; DC, disease causing; Del, deleterious; 
MAF, minor allele frequency; MT, mutation taster; NA, not available; PP2, PolyPhen-2 prediction score 
Humvar; PROVEAN, Protein Variation Effect Analyzer; SIFT, Sorting Intolerant from Tolerant; SNP, single 
nucleotide polymorphism. a cDNA mutations are numbered according to the human cDNA reference sequence 
NM_004183; + 1 corresponds to the A of ATG translation initiation codon. b Amino acid residue is continually 
conserved throughout evolution including the species as indicated. c dbSNP database (http:// www. ncbi. nlm. 
nih. gov/ SNP). d gnomAD browser (http:// gnomad. broad insti tute. org/). e PolyPhen-2 prediction score HumVar 
ranges from 0 to 1.0; 0 = benign, 1.0 = probably damaging (http:// genet ics. bwh. harva rd. edu/ pph2/). f Mutation 
taster (http:// www. mutat ionta ster. org/). gPROVEAN (http:// prove an. jcvi. org/ index. php). hSIFT (http:// sift. jcvi. 
org/).
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5-Patient II-2) with numerous large granular deposits in the cornea visited our clinic. She experienced intermit-
tent eye pain due to recurrent corneal erosion, although her BCVA was 20/25 in both eyes (Fig. 3a). Whole-
TGFBI sequencing and pedigree analysis of the patient revealed that she harboured compound heterozygous 
p.(Arg124His) and p.(Tyr88Cys) mutations (Table 1, Supplementary Fig. S1b). No corneal deposit was detected 
in her 46-year-old father who harboured p.(Tyr88Cys) heterozygous mutation alone, whereas her 45-year-old 
mother harbouring p.(Arg124His) heterozygous mutation showed typical GCD2 heterozygous phenotype with 
discoid granular and star-shaped corneal deposits in both eyes (Fig. 3a). The proband’s sibling, with no mutation, 
showed no corneal opacity.
A 28-year-old man (Proband 6; Family 6-Patient III-1) was referred to our clinic owing to visual disturbance 
due to corneal opacities in both eyes. BCVA of the patient was 20/40 for the right eye and 20/35 for the left eye, 
with both eyes showing confluent granular deposits and dense lattice deposits (Fig. 3b). Genetic analysis of 
the proband showed p.(Arg124His) and p.(Arg257Pro) missense mutations in TGFBI (Table 1, Supplementary 
Fig. S1c). His 54-year-old father, who only harboured heterozygous p.(Arg257Pro) mutation, did not show any 
deposit (Fig. 3b), whereas his 51-year-old mother and 49-year-old maternal uncle, both GCD2 heterozygotes, 
showed typical annular granular deposits with deep linear deposits (Fig. 3b), confirming trans-phase mutations 
in the proband.
Figure 2.  Compound heterozygous mutations, p.(Ile247Asn) and p.(Arg124His), in TGFBI. (a) Slit-lamp 
photographs of Proband 4 (Family 4). Intensive snowflake-like corneal deposits were noted at the age of 
25 years, and rapid recurrence occurred after phototherapeutic keratectomy (PTK). Following deep anterior 
lamellar keratoplasty (DALK), the cornea has been well-maintained since the past 3 years. (b) Pedigree of 
Family 4 confirmed compound heterozygosity. (c) Slit-lamp photographs of the parents of Proband 4. The 
mother, who only had heterozygous p.(Arg124His) mutation in TGFBI, showed milder phenotypes than the 
son, and the father, who had heterozygous p.(Ile247Asn) mutation in TGFBI, showed a clear cornea. Although 
TGFBI p.(Ile247Asn) mutation itself was silent, when accompanying p.(Arg124His) mutation, phenotypes of 
granular corneal dystrophy 2 became extensive and recurrence occurred rapidly after PTK.
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Figure 3.  TGFBI p.(Tyr88Cys), p.(Arg257Pro), and p.(Asn544Ser) mutations were accompanied by 
p.(Arg124His) mutation in patients with severe phenotypes. (a) Slit-lamp photographs of Proband 5 and her 
parents (Family 5). The proband showed numerous large discoid granular deposits. However, her mother 
carrying heterozygous p.(Arg124His) variant showed age-appropriate disease pattern, while the father carrying 
heterozygous p.(Tyr88Cys) variant showed no disease phenotype. (b) Slit-lamp photographs of the members 
of Family 6. Compound heterozygosity of TGFBI p.(Arg124His) and p.(Arg257Pro) mutations caused severe 
GCD2 phenotypes compared to the heterozygosity of TGFBI p.(Arg124His) mutation alone, although 
heterozygosity of TGFBI p.(Arg257Pro) mutation did not cause disease. (c) Slit-lamp photographs of Proband 7 
carrying compound heterozygous mutations of TGFBI (p.(Arg124His) and p.(Asn544Ser)). The recurrence was 
very rapid after phototherapeutic keratectomy (PTK).
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6986  | https://doi.org/10.1038/s41598-021-86414-9
www.nature.com/scientificreports/
A 32-year-old woman (Proband 7; Family 7-Patient III-11), who had undergone laser-assisted sub-epithelial 
keratomileusis (LASEK) in both her eyes at another clinic, visited our clinic with complains of visual distur-
bance, with severe diffuse stromal opacities. She underwent PTK in our clinic to remove the opacity in her right 
eye; however, her corneal opacity recurred rapidly after PTK (Fig. 3c). Genetic and pedigree analyses revealed 
that she carried both p.(Arg124His) and p.(Asn544Ser) mutations in a different allele of TGFBI (Table 1, Sup-
plementary Fig. S1d). We could not find older living family members with p.(Asn544Ser) mutation alone in her 
family, and the younger members (aged 15 and 4 years) who harboured p.(Asn544Ser) mutation alone did not 
show any opacity.
We happened to identify a 22-year-old woman with p.(Asn544Ser) mutation alone in a different family during 
routine genetic screening before refractive surgery, following which we analysed the whole family of the patient 
for p.(Asn544Ser) mutation (Supplementary Fig. S1g). Two family members, one 82-year-old woman and the 
other 74-year-old woman, who were p.(Asn544Ser) heterozygotes, did not show any corneal opacity. A 56-year-
old woman with p.(Asn544Ser) mutation alone (Family 10-Patient III-5), who had undergone LASEK 4 years 
ago on her left cornea only, to correct myopia of 2.5 D, showed single, small, white opacity, 1.4 mm away from 
the pupil centre (Supplementary Fig. S1h).
Heterozygous patients with GCD2 and additional nonsense mutations (p.(Arg179*) or 
p.(Tyr468*)) in the opposite allele of TGFBI. A 35-year-old woman (Proband 8; Family 8-Patient III-
2) visited our clinic for treating extensive severe multiple discoid granular corneal deposits, resembling those 
observed in homozygous GCD2, and diffuse haze in both eyes. She had BCVA of 20/50 in both eyes and no 
other ocular history (Fig.  4a). After whole-TGFBI sequencing, she was found to carry compound heterozy-
gous p.(Arg124His) and p.(Arg179*) [CGA (Arg) → TGA (stop codon)] mutations (Table  1). The proband’s 
76-year-old father and 36-year-old elder sister were found to be p.(Arg124His) heterozygotes with their corneas 
expressing the typical GCD2 phenotypes (father: superficial breadcrumb-like deposits with deep spiny deposits) 
(Fig. 4a). The younger sister, without mutation, had no corneal abnormality. The proband’s mother and two 
maternal aunts, who were 70-, 64-, and 56-year-old, respectively, showed clear corneas despite having a mis-
sense mutation (p.(Arg179*)) in TGFBI (Fig. 4a, and Supplementary Fig. S1e). The findings for this family have 
been previously  reported21, except for the results of the genetic tests of the proband’s mother and maternal aunts.
A 21-year-old man (Proband 9; Family 9-Patient II-1) with numerous large granular deposits in both eyes 
visited our clinic (Fig. 4b). Both p.(Arg124His) and p.(Tyr468*) [TAT (Tyr) → TAA (stop codon)] mutations 
were detected in TGFBI (Table 1). The proband’s 44-year-old mother harbouring p.(Arg124His) mutation showed 
only mild typical corneal opacities compared to the proband (Fig. 4b). Although we could not test whether the 
his father harboured p.(Tyr468*) mutation, the proband was likely compound heterozygous for these mutations, 
assuming that p.(Tyr468*) mutation did not occur de novo (Supplementary Fig. S1f.).
Discussion
The current study demonstrated that simultaneous presence of mutations, such as p.(His174Asp), p.(Ile247Asn), 
p.(Tyr88Cys), p.(Arg257Pro), p.(Asn544Ser), p.(Arg179*), and p.(Tyr468*), along with p.(Arg124His), in TGFBI 
in a compound heterozygous pattern could result in the severe phenotype of GCD2. p.(Tyr88Cys), p.(Arg179*), or 
p.(Tyr468*) mutation showed increased number or size of granules, while the other mutations showed increased 
amounts of linear deposits. Compound mutations of p.(Arg124His) with p.(Asn544Ser) or p.(Arg179*) have been 
reported previously, without identifying the phenotype of family members having p.(Asn544Ser) or p.(Arg179*) 
mutation  alone16,21; such aspects have been presented herein. The remaining five variants are newly detected 
mutations.
Double mutations with p.(Arg124His) in TGFBI have been identified in only 3 cases to  date16,20,21, out of 12 
TGFBI double mutations reported in 13 previous studies (Supplementary Table S2)11–23. Whether the previously 
reported p.(Ser104Lysfs*27) and p.(Arg179*) mutations carrying p.(Arg124His)20,21 were compound heterozy-
gous, could not be confirmed because of the refusal of family members for evaluation. We found five novel and 
two known TGFBI variants in compound heterozygotes with p.(Arg124His) and verified that each of the second 
mutation identified caused no corneal abnormality when present by itself. These results had significant clinical 
implications, since unexpected severe p.(Arg124His) variant can arise in families when p.(Arg124His) mutation 
is combined with the silent mutations mentioned above.
The cause of the presentation of the severe phenotype of GCD2 in individuals with compound heterozygous 
mutations of TGFBI is not yet clear. Mixture of TGFBIps obtained from the culture media of cells expressing 
p.(His174Asp)- or p.(Ile247Asn), and p.(Arg124His)-mutant corneal fibroblasts, showed increased oligomer 
and aggregate formation in in vitro experiments. Several studies have reported that homozygous GCD2 corneal 
fibroblasts showed more oxidative stress and impaired autophagy functions, resulting in a greater accumulation 
of TGFBIp in the corneal  fibroblasts24,25. Further, intracellular TGFBIp is reportedly cleared out via lysosomes, 
and this function is impaired in cultured GCD2 corneal  fibroblasts26. We suspected the double production of 
mutated TGFBIps from p.(Arg124His) allele and heterozygous mutation in opposite alleles to result in an intracel-
lular TGFBIp status closer to that seen in GCD2 homozygotes than in heterozygotes. Elucidating the mechanism 
underlying the formation of differential phenotypes for each different second mutation requires further studies.
Interestingly, all the heterozygotes of p.(His174Asp) (70-year-old), p.(Ile247Asn) (77- and 62-year-old), 
p.(Tyr88Cys) (46-year-old), p.(Arg257Pro) (64- and 54-year-old), and p.(Arg179*) (70-, 64-, 61-, and 56-year-
old) mutations showed clear corneas even at advanced age. Moreover, p.(Asn544Ser) heterozygotes, both 82- and 
74-year-old Korean women with the mutation, showed clear cornea (Supplementary Fig. S1h). The 56-year-old 
woman with p.(Asn544Ser) mutation alone, who had undergone LASEK 4 years ago, showed only a small opacity. 
We could not determine whether this opacity was a result of scarring after LASEK or the exacerbation of silent 
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cornea having p.(Asn544Ser)-only mutation. A study conducted in Japan reported lattice corneal dystrophy in a 
68-year-old patient with a p.(Asn544Ser) mutation  only27, although the underlying cause could not be precisely 
explained. However, the data suggested that more reports of cases with silent second mutations would be required 
to verify the safety of refractive surgery. There are abundant reports of exacerbation of TGFBI-related corneal 
dystrophies, including GCD2 or GCD1 with deposits, following corneal trauma such as laser-assisted in situ 
 keratomileusis28,29, LASEK, photorefractive keratectomy, and refractive  keratotomy4,30,31.
Two types of mutations with stop codons, p.(Arg179*) or p.(Tyr468*), combined with p.(Arg124His) mutation 
in TGFBI showed similar phenotypes in our study, with extensive discoid granular deposits resembling those in 
homozygous GCD2. Yam et al. reported a 31-year-old patient carrying compound heterozygous p.(Arg124His) 
and p.(Leu103Leufs*28) mutations (c.307_308delCT induced frame shift and finally resulted in premature stop 
at position 130) in TGFBI, showing a pattern of corneal opacities very similar to that in our  cases20. In the present 
study, p.(Arg179*) or p.(Tyr468*) stop codon was generated at codon 179 or 468, while in the study conducted 
by Yam et al., the stop codon occurred with a frame shift; however, the phenotype remained very similar. These 
data collectively showed that the presence of compound heterozygous mutation with the stop codon in one allele 
and p.(Arg124His) mutation in another could result in extensive granular deposits. Poulsen et al.32 reported that 
the macroscopic, microscopic, and ultrastructural appearance of TGFBI-null mouse cornea remain unaffected, 
suggesting that partial or complete knockdown of TGFBI could be a potential therapy against TGFBI-linked 
Figure 4.  Nonsense mutations of TGFBI (p.(Arg179*) and p.(Tyr468*)) manifested severe granular corneal 
dystrophy 2 (GCD2) phenotypes. (a) Slit-lamp photographs of members of Family 8. Extensive multiple discoid 
granular deposits, with some annular deposits, were detected, resembling the features of homozygous GCD2 in 
Proband 8 carrying TGFBI p.(Arg179*) and p.(Arg124His) mutations. Her father carrying heterozygous TGFBI 
p.(Arg124His) mutation showed milder phenotypes than the proband, and the mother carrying heterozygous 
TGFBI p.(Arg179*) showed no corneal opacity. (b) Slit-lamp photographs of Proband 9 and his mother. 
Proband 9 harboured compound heterozygous TGFBI p.(Tyr468*) and p.(Arg124His) mutations and showed 
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corneal dystrophies. Currently, correction of p.(Arg124His) mutation in cornea by knocking out the mutated 
allele is being attempted for the treatment of  GCD233,34. Our present data indicate that the knockout of the allele 
should be very precise during gene therapy, in case of the heterozygote, such that only the allele containing 
p.(Arg124His) mutation is treated, leaving the normal-sequence allele intact. If the wild-type allele is altered 
to stop codon while the p.(Arg124His)-mutant allele is kept unchanged, it may result in the final corneal lesion 
being similar to that observed in compound heterozygotes with stop codon in the present study.
Family 1 in this study was previously reported to have extremely varied GCD2 heterozygote  phenotypes10. 
However, the exact reason for severe phenotypic variability in the family was not known then; here, we showed 
the compound heterozygous mutation to be a causative factor among multiple genetic and environmental fac-
tors. Moreover, we showed that the patients with compound heterozygous TGFBI mutations experienced rapid 
recurrence after PTK. Identifying the reason underlying why the cornea remaining clear for an extended period 
after DALK in Proband 4 of this study would require further investigation.
In conclusion, this study reported five novel and two known genetic mutations that can predict the occurrence 
of the severe phenotype of heterozygous GCD2. Since phenotypic variations may indicate the presence of a new 
genetic change, whole-TGFBI sequencing would be necessary when a heterozygous patient with severe GCD2 
is identified. Identification of cases with second mutations could more thoroughly explain the pathophysiology 
of GCD2.
Methods
Clinical investigation. This study was approved by the Institutional Review Board of Yonsei University 
College of Medicine (IRB No. 4–2012-0209) and followed the tenets of the Declaration of Helsinki. Written 
informed consent was obtained from all participants. All participants agreed to have their photos published. 
The patients who visited Severance Hospital from January 2007 to October 2020 underwent a detailed ophthal-
mological examination, including BCVA test, intraocular pressure measurement, slit-lamp examination, and 
slit-lamp photograph analysis. Among the patients with GCD2, the ones who presented severe phenotypes and 
had no other history of ocular or systemic diseases were selected as candidates for whole-TGFBI sequencing. 
After identifying other mutations, in addition to p.(Arg124His), family members were enrolled in the study to 
perform segregation analysis.
Genomic DNA preparation and mutation analysis. TGFBI was analysed as described previously, after 
receiving informed consent from the  participants29. Briefly, 2 ml of blood was drawn from each subject and 
genomic DNA was extracted from their peripheral leukocytes using a QIAamp DNA Blood Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Primers were designed to amplify all 17 exons 
of TGFBI (Supplementary Table S1). Each polymerase chain reaction (PCR) was performed using a 20-μl reac-
tion mixture (Maxime PCR Premix kit; iNtRON Biotechnology, Seongnam-si, Gyeonggi-do, Korea) contain-
ing 100 ng of genomic DNA, 10 pmol each of forward and reverse primers, and distilled water. Samples were 
amplified through 35 PCR cycles; each cycle consisted of denaturation for 20 s at 94 °C, annealing for 15 s at 
58 °C, and extension for 50 s at 72 °C. PCR was performed using a 96-well thermal cycler (Applied Biosystems, 
Foster City, CA, USA). Subsequently, Sanger sequencing was performed for all exons; to screen for mutations, 
we compared the DNA sequence of patients with the complementary DNA sequence of TGFBI obtained from 
GenBank (NC_000005.10).
TGFBIp oligomer formation, aggregate analysis, and immunoblotting. To determine oligomer 
formation and aggregation ability, both wild-type and p.Arg124His-mutant TGFBIp were incubated with 
either p.(His174Asp)- or p.(Ile247Asn)-mutant TGFBIp for 1 h at 37 °C, following which immunoblotting was 
 performed35. Details are available in the Supplementary Methods.
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